New hope for young blood cancer patients: QUAIL-100 trial launches
NCT ID NCT07573111
First seen May 12, 2026 · Last updated May 12, 2026
Summary
This early-stage study tests a new drug, QUAIL-100, in 12 children and young adults with high-risk leukemia or myelodysplastic syndrome who have already received a special type of stem cell transplant. The main goal is to check the drug's safety and side effects. Participants will receive a single dose of QUAIL-100 to see if it can help control their disease without causing serious harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lucille Packard Children's Hospital of Stanford University
Palo Alto, California, 94304, United States
Conditions
Explore the condition pages connected to this study.